Cardiovascular Drugs Market Size and Outlook 2031

Report Description

Key Insights	Details
Forecast Period	2025 - 2030
Market Size (2025)	USD 159.59 Billion
CAGR (2026-2031)	3.28%
Fastest Growing Segment	Heart-failure drugs (3.70% CAGR through 2030)
Largest Market	North America
Market Size (2031)	USD 193.69 Billion

Market Overview

The Global Cardiovascular Drugs Market is expected to grow from USD 159.59 Billion in 2025 to USD 193.69 Billion by 2031 at a 3.28% CAGR. Cardiovascular drugs encompass pharmaceutical agents employed in the prevention, treatment, and management of diverse heart and blood vessel conditions, including hypertension, dyslipidemia, coronary artery disease, and heart failure. The market's growth is primarily driven by the escalating global prevalence of cardiovascular diseases, the worldwide aging population, and the increasing adoption of unhealthy lifestyles. These factors collectively contribute to a sustained demand for effective therapeutic interventions.

According to the American Heart Association's 2026 Statistics Update, published January 2026, the global prevalence of cardiovascular disease was 612.06 million in 2021, with approximately 19.41 million global deaths attributed to CVD in the same year. Additionally, a World Health Organization update issued in September 2025 estimated 1.4 billion adults were living with hypertension during 2024. A significant challenge that could impede market expansion is the high cost associated with research and development for novel cardiovascular therapies, requiring substantial investment for innovation.

Key Market Drivers

Rising global cardiovascular burden drives demand for therapies
The increasing global burden of cardiovascular diseases serves as a primary driver for the cardiovascular drugs market due to the escalating demand for effective treatment and management solutions. The pervasive nature of conditions such as ischemic heart disease necessitates continuous pharmaceutical innovation to address widespread health challenges. According to the World Health Organization's Global Health Estimates, released in October 2026, ischaemic heart disease alone accounted for approximately 9.5 million deaths and 210 million disability-adjusted life years in 2023. This substantial disease burden underscores the critical need for a diverse range of therapeutic interventions, from preventative medications to advanced treatments for complex cardiac conditions, thereby fueling market growth.

Aging population and ongoing R&D investment propel market expansion
Alongside this, the aging global population significantly contributes to market expansion as cardiovascular disease prevalence rises with age. As individuals live longer, the cumulative exposure to risk factors and the natural physiological changes associated with aging increase susceptibility to various heart and vascular conditions, driving a sustained demand for long-term pharmacological management. According to I'm Alive, citing the World Health Organization in March 2026, over 1.2 billion people worldwide are now aged 60 or older. Furthermore, the pharmaceutical industry continues to invest heavily in addressing these widespread health challenges. According to PhRMA, a recent report highlights that 200 medicines are currently in development in the United States by biopharmaceutical companies for cardiovascular diseases.

Download Free Sample Report

Key Market Challenges

High R&D Costs Impede Market Growth
The high cost associated with research and development for novel cardiovascular therapies presents a significant impediment to the expansion of the global cardiovascular drugs market. The extensive resources required for drug discovery, rigorous preclinical testing, and multiple phases of clinical trials place a substantial financial burden on pharmaceutical companies. This capital-intensive process often spans a decade or more before a potential product reaches market, frequently without a guarantee of regulatory approval or commercial success.

Investment Pressure Limits Innovation and Pipeline Diversity
This financial outlay inherently deters investment in certain novel cardiovascular drug candidates, particularly those targeting rarer conditions or requiring particularly complex development pathways, thereby limiting pipeline diversification. According to PhRMA, in 2025, member companies collectively invested more than $110 billion in research and development activities. Such substantial investments underscore the financial pressures on developers, leading to a more conservative approach to innovation and potentially constraining the availability of groundbreaking treatments for a wide array of cardiovascular conditions. This directly impacts market growth by slowing the introduction of new, advanced therapeutic interventions.

Key Market Trends

Emergence of Novel Therapeutics and Regulatory Approvals
The emergence of novel therapeutic classes significantly impacts the global cardiovascular drugs market by introducing innovative mechanisms of action for conditions with limited prior options. These new drug categories offer enhanced precision, targeting specific disease pathways more effectively than conventional treatments. For instance, selective small molecule transthyretin stabilizers are expanding treatment for rare cardiac amyloidosis. According to BridgeBio Pharma, Inc., November 3, 2026, acoramidis, a transthyretin stabilizer, received approvals from the U.S. FDA, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, and several other global regulatory bodies. This widespread regulatory acceptance of advanced therapies drives market expansion by addressing critical unmet medical needs.

AI-Driven Discovery Accelerates Cardiovascular Drug Development
The increased integration of Artificial Intelligence in drug discovery and development is a transformative trend, accelerating target identification and streamlining preclinical research within the cardiovascular drugs market. AI-driven platforms analyze extensive datasets to predict molecular interactions, optimize compound properties, and enhance lead candidate selection. This expedites development timelines and reduces costs, enabling pharmaceutical companies to explore complex disease mechanisms more efficiently. According to pharmaphorum, October 16, 2026, AstraZeneca paid $40 million upfront to insitro for its AI platform to discover new drug targets for liver and heart conditions, with $1.46 billion in potential milestones. These substantial investments underscore the industry's strategic reliance on AI for future cardiovascular drug innovation.

Segmental Insights

Drivers of Growth in Heart-Failure Therapies
The heart-failure drugs segment stands out as the fastest-growing area within the Global Cardiovascular Drugs Market. This rapid expansion is primarily driven by an aging global population and the increasing prevalence of cardiovascular diseases, such as hypertension and diabetes, which are significant precursors to heart failure. Furthermore, continuous advancements in pharmaceutical research have introduced novel drug classes and innovative therapies, significantly improving patient outcomes and expanding treatment options. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have also played a crucial role by accelerating approvals for these advanced therapies, further stimulating market dynamics and meeting the escalating demand for effective heart failure management solutions.

Regional Insights

North America Leads the Global Cardiovascular Drugs Market
North America consistently leads the global cardiovascular drugs market due to its highly developed healthcare infrastructure and substantial healthcare spending. The region benefits from robust pharmaceutical research capabilities and extensive clinical development initiatives, fostering the early adoption of innovative cardiovascular therapies. Favorable regulatory support, particularly from institutions like the Food and Drug Administration, coupled with strong reimbursement frameworks, significantly enhances market accessibility for advanced treatments. These factors, alongside a high prevalence of cardiovascular diseases, collectively drive North America's dominance in the market.

Recent Developments

In November 2025, Amgen announced detailed results from its Phase 3 VESALIUS-CV clinical trial, demonstrating that its lipid-lowering antibody, Repatha (evolocumab), significantly reduced major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke. When added to existing lipid-lowering therapies, Repatha achieved a 25% reduction in the risk of major adverse cardiovascular disease and a 36% decrease in the risk of first heart attacks. This positioned Repatha as the first and only PCSK9 inhibitor to show a significant reduction of cardiovascular events for both high-risk primary and secondary prevention.
In June 2025, Novartis and ProFound Therapeutics initiated a four-year strategic collaboration valued at $750 million per target to advance novel cardiovascular therapies. This partnership was designed to combine Novartis's expertise in cardiovascular drug development with ProFound's proprietary ProFoundry Platform. The platform utilizes advanced protein detection technologies to identify and validate new protein targets and explore their therapeutic potential, aiming to unlock first-in-class drug candidates for cardiovascular diseases. ProFound Therapeutics received $25 million in upfront and near-term milestone payments.
In March 2024, Novo Nordisk expanded its cardiovascular drug pipeline through the acquisition of Cardior Pharmaceuticals, a developer of genetic medicines specializing in heart failure treatments. Novo Nordisk committed up to €1.025 billion (approximately $1.1 billion) for the acquisition, which included an upfront payment along with potential development and commercial milestone payments. This strategic move aimed to integrate Cardior's lead RNA-based therapy, currently in mid-stage clinical testing, into Novo Nordisk's portfolio. The acquisition was highlighted as an important step in the company's broader strategy to establish a stronger presence in the cardiovascular disease area.
In March 2024, the U.S. Food and Drug Administration (FDA) approved an expanded label indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. This approval marked a significant development as it was the first time a weight-loss medication received an indication for cardiovascular risk reduction in this patient population. The decision was based on data from the SELECT trial, a large study demonstrating a 20% relative reduction in the risk of major cardiovascular events.

Key Market Players

Amgen Inc
Novartis AG
Boehringer Ingelheim International GmbH
Pfizer Inc.
Baxter
Merck & Co., Inc.
Bristol Myers Squibb
Novo Nordisk
Abbott
Lupin

By Drug Class	By Disease Indication	By Route of Administration	By Distribution Channel	By Region
Anticoagulants Heart-failure drugs Antihypertensives Lipid-lowering agents Pulmonary-hypertension drugs Antiarrhythmics	Hypertension Heart failure Coronary-artery disease (CAD) Dyslipidemia	Oral Injectable (incl. Injectable / IV)	Hospitals / Hospital pharmacies Pharmacies / Online pharmacies More (Other distribution)	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiovascular Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cardiovascular Drugs Market, By Drug Class:

Anticoagulants
Heart-failure drugs
Antihypertensives
Lipid-lowering agents
Pulmonary-hypertension drugs
Antiarrhythmics

Cardiovascular Drugs Market, By Disease Indication:

Hypertension
Heart failure
Coronary-artery disease (CAD)
Dyslipidemia

Cardiovascular Drugs Market, By Route of Administration:

Oral
Injectable (incl. Injectable / IV)

Cardiovascular Drugs Market, By Distribution Channel:

Hospitals / Hospital pharmacies
Pharmacies / Online pharmacies
More (Other distribution)

Cardiovascular Drugs Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cardiovascular Drugs Market.

Available Customizations:

Global Cardiovascular Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Cardiovascular Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cardiovascular Drugs Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Drug Class (Anticoagulants, Heart-failure drugs, Antihypertensives, Lipid-lowering agents, Pulmonary-hypertension drugs, Antiarrhythmics)

5.2.2. By Disease Indication (Hypertension, Heart failure, Coronary-artery disease (CAD), Dyslipidemia)

5.2.3. By Route of Administration (Oral, Injectable (incl. Injectable / IV))

5.2.4. By Distribution Channel (Hospitals / Hospital pharmacies, Pharmacies / Online pharmacies, More (Other distribution))

5.2.5. By Region

5.2.6. By Company (2025)

5.3. Market Map

6. North America Cardiovascular Drugs Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Drug Class

6.2.2. By Disease Indication

6.2.3. By Route of Administration

6.2.4. By Distribution Channel

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Cardiovascular Drugs Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Drug Class

6.3.1.2.2. By Disease Indication

6.3.1.2.3. By Route of Administration

6.3.1.2.4. By Distribution Channel

6.3.2. Canada Cardiovascular Drugs Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Drug Class

6.3.2.2.2. By Disease Indication

6.3.2.2.3. By Route of Administration

6.3.2.2.4. By Distribution Channel

6.3.3. Mexico Cardiovascular Drugs Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Drug Class

6.3.3.2.2. By Disease Indication

6.3.3.2.3. By Route of Administration

6.3.3.2.4. By Distribution Channel

7. Europe Cardiovascular Drugs Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Class

7.2.2. By Disease Indication

7.2.3. By Route of Administration

7.2.4. By Distribution Channel

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Cardiovascular Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Drug Class

7.3.1.2.2. By Disease Indication

7.3.1.2.3. By Route of Administration

7.3.1.2.4. By Distribution Channel

7.3.2. France Cardiovascular Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Drug Class

7.3.2.2.2. By Disease Indication

7.3.2.2.3. By Route of Administration

7.3.2.2.4. By Distribution Channel

7.3.3. United Kingdom Cardiovascular Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Drug Class

7.3.3.2.2. By Disease Indication

7.3.3.2.3. By Route of Administration

7.3.3.2.4. By Distribution Channel

7.3.4. Italy Cardiovascular Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Drug Class

7.3.4.2.2. By Disease Indication

7.3.4.2.3. By Route of Administration

7.3.4.2.4. By Distribution Channel

7.3.5. Spain Cardiovascular Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Drug Class

7.3.5.2.2. By Disease Indication

7.3.5.2.3. By Route of Administration

7.3.5.2.4. By Distribution Channel

8. Asia Pacific Cardiovascular Drugs Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Disease Indication

8.2.3. By Route of Administration

8.2.4. By Distribution Channel

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Cardiovascular Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Disease Indication

8.3.1.2.3. By Route of Administration

8.3.1.2.4. By Distribution Channel

8.3.2. India Cardiovascular Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Disease Indication

8.3.2.2.3. By Route of Administration

8.3.2.2.4. By Distribution Channel

8.3.3. Japan Cardiovascular Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Disease Indication

8.3.3.2.3. By Route of Administration

8.3.3.2.4. By Distribution Channel

8.3.4. South Korea Cardiovascular Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Class

8.3.4.2.2. By Disease Indication

8.3.4.2.3. By Route of Administration

8.3.4.2.4. By Distribution Channel

8.3.5. Australia Cardiovascular Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Class

8.3.5.2.2. By Disease Indication

8.3.5.2.3. By Route of Administration

8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Cardiovascular Drugs Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Class

9.2.2. By Disease Indication

9.2.3. By Route of Administration

9.2.4. By Distribution Channel

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Cardiovascular Drugs Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Class

9.3.1.2.2. By Disease Indication

9.3.1.2.3. By Route of Administration

9.3.1.2.4. By Distribution Channel

9.3.2. UAE Cardiovascular Drugs Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Class

9.3.2.2.2. By Disease Indication

9.3.2.2.3. By Route of Administration

9.3.2.2.4. By Distribution Channel

9.3.3. South Africa Cardiovascular Drugs Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Class

9.3.3.2.2. By Disease Indication

9.3.3.2.3. By Route of Administration

9.3.3.2.4. By Distribution Channel

10. South America Cardiovascular Drugs Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Disease Indication

10.2.3. By Route of Administration

10.2.4. By Distribution Channel

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Cardiovascular Drugs Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Class

10.3.1.2.2. By Disease Indication

10.3.1.2.3. By Route of Administration

10.3.1.2.4. By Distribution Channel

10.3.2. Colombia Cardiovascular Drugs Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Class

10.3.2.2.2. By Disease Indication

10.3.2.2.3. By Route of Administration

10.3.2.2.4. By Distribution Channel

10.3.3. Argentina Cardiovascular Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Class

10.3.3.2.2. By Disease Indication

10.3.3.2.3. By Route of Administration

10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Cardiovascular Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Amgen Inc

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Novartis AG

15.3. Boehringer Ingelheim International GmbH

15.4. Pfizer Inc.

15.5. Baxter

15.6. Merck & Co., Inc.

15.7. Bristol Myers Squibb

15.8. Novo Nordisk

15.9. Abbott

15.10. Lupin

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Cardiovascular Drugs Market in 2025?

Which is the dominating region in the Global Cardiovascular Drugs Market?

Which is the fastest growing segment in the Global Cardiovascular Drugs Market?

What is the expected growth rate of the Global Cardiovascular Drugs Market?